GALE
Oct 07 2022
To assess the long-term efficacy and safety of multiple intravitreal injections of APL-2 in subjects with geographic atrophy secondary to age-related macular degeneration.
Read MoreCONCERTO
Oct 07 2022
To determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Read MoreVILLA
Oct 07 2022
To evaluate safety and tolerability of the Port Delivery System (PDS) in patients with neovascular age-related macular degeneration (nAMD).
Read MoreHONU
Oct 07 2022
The purpose of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced AMD stages.
Read MoreATMOSPHERE
Aug 24 2021
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Read MorePEP
Aug 24 2021
Patient Experience and Preference (PEP) Study in nAMD and DME Sponsor: Hoffmann-La Roche Ltd
Read MoreBIM2
Dec 01 2020
To identify whether genetic variation or polymorphism in genes that impact angiogenesis can be identified as biomarkers for responsiveness to anti-VEGF therapy in patients with neovascular age-related macular degeneration.
Read MoreCATALINA
Dec 01 2020
A Phase II Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (CATALINA) Sponsor: NGM Biopharmaceuticals, Inc.…
Read MoreMeet Alicia Wolf, Social Worker with UW Health Patient Resources
Nov 03 2020
Patient Services in Action: Alicia Wolf As the social worker for ophthalmology services, Alicia Wolf has been assisting our providers in connecting their patients to resources to cope with low vision, as…
Read More